Olutasidenib Explained
Tradename: | Rezlidhia |
Dailymedid: | Olutasidenib |
Routes Of Administration: | By mouth |
Atc Prefix: | None |
Legal Us: | Rx-only |
Legal Us Comment: | [1] |
Cas Number: | 1887014-12-1 |
Pubchem: | 118955396 |
Iuphar Ligand: | 10319 |
Drugbank: | DB16267 |
Chemspiderid: | 72380144 |
Unii: | 0T4IMT8S5Z |
Kegg: | D12483 |
Chembl: | 4297610 |
Pdb Ligand: | PWV |
Synonyms: | FT-2102 |
C: | 18 |
H: | 15 |
Cl: | 1 |
N: | 4 |
O: | 2 |
Smiles: | C[C@H](NC1=CC=C(C#N)N(C)C1=O)C1=CC2=C(NC1=O)C=CC(Cl)=C2 |
Stdinchi: | InChI=1S/C18H15ClN4O2/c1-10(21-16-6-4-13(9-20)23(2)18(16)25)14-8-11-7-12(19)3-5-15(11)22-17(14)24/h3-8,10,21H,1-2H3,(H,22,24)/t10-/m0/s1 |
Stdinchikey: | NEQYWYXGTJDAKR-JTQLQIEISA-N |
Olutasidenib, sold under the brand name Rezlidhia, is an anticancer medication used to treat relapsed or refractory acute myeloid leukemia with a susceptible IDH1 mutation.[2] Olutasidenib is an isocitrate dehydrogenase-1 (IDH1) inhibitor. It is taken by mouth.
The most common adverse reactions include nausea, fatigue/malaise, arthralgia, constipation, leukocytosis, dyspnea, fever, rash, mucositis, diarrhea, and transaminitis.
Olutasidenib was approved for medical use in the United States in December 2022,[3] [4] [5] [6] based on the phase 1 results of a phase 1/2 trial.[7]
Medical uses
Olutasidenib is indicated for the treatment of adults with relapsed or refractory acute myeloid leukemia with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test.
Society and culture
Names
Olutasidenib is the international nonproprietary name.[8]
Further reading
- Liu X, Gong Y . Isocitrate dehydrogenase inhibitors in acute myeloid leukemia . Biomarker Research . 7 . 22 . 2019 . 31660152 . 6806510 . 10.1186/s40364-019-0173-z . free . doi .
- Watts JM, Baer MR, Yang J, Prebet T, Lee S, Schiller GJ, Dinner SN, Pigneux A, Montesinos P, Wang ES, Seiter KP, Wei AH, De Botton S, Arnan M, Donnellan W, Schwarer AP, Récher C, Jonas BA, Ferrell PB, Marzac C, Kelly P, Sweeney J, Forsyth S, Guichard SM, Brevard J, Henrick P, Mohamed H, Cortes JE . Olutasidenib alone or with azacitidine in IDH1-mutated acute myeloid leukaemia and myelodysplastic syndrome: phase 1 results of a phase 1/2 trial . The Lancet Haematology . 10. 1. e46–e58. November 2022 . 36370742 . 10.1016/S2352-3026(22)00292-7 . 253471380 .
External links
- Web site: Olutasidenib . U.S. National Library of Medicine . Drug Information Portal .
Notes and References
- Web site: Rezlidhia- olutasidenib capsule . DailyMed . U.S. National Library of Medicine . 13 December 2022 . 21 January 2023.
- Web site: Theoret MR . REZLIDHIA (olutasidenib) capsules . Approval Letter . December 2022 . U.S. Food and Drug Administration .
- Web site: FDA approves olutasidenib for relapsed or refractory acute myeloid leukemia with a susceptible IDH1 mutation . U.S. Food and Drug Administration (FDA) . 1 December 2022 . 20 December 2022.
- Rigel Announces U.S. FDA Approval of Rezlidhia (olutasidenib) for the Treatment of Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia with a Susceptible IDH1 Mutation . Rigel Pharmaceuticals, Inc. . 1 December 2022 . 2 December 2022.
- Rigel Announces U.S. FDA Approval of Rezlidhia (olutasidenib) for the Treatment of Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia with a Susceptible IDH1 Mutation . Rigel Pharmaceuticals . PR Newswire . 1 December 2022 . 2 December 2022.
- Kang C . Olutasidenib: First Approval . Drugs . 83 . 4 . 341–346 . March 2023 . 36848032 . 10.1007/s40265-023-01844-1 . 257218495 .
- Watts JM, Baer MR, Yang J, Prebet T, Lee S, Schiller GJ, Dinner SN, Pigneux A, Montesinos P, Wang ES, Seiter KP, Wei AH, De Botton S, Arnan M, Donnellan W, Schwarer AP, Récher C, Jonas BA, Ferrell PB, Marzac C, Kelly P, Sweeney J, Forsyth S, Guichard SM, Brevard J, Henrick P, Mohamed H, Cortes JE . Olutasidenib alone or with azacitidine in IDH1-mutated acute myeloid leukaemia and myelodysplastic syndrome: phase 1 results of a phase 1/2 trial . The Lancet. Haematology . 10 . 1 . e46–e58 . January 2023 . 36370742 . 10.1016/s2352-3026(22)00292-7 . 253471380 .
- ((World Health Organization)) . 2019 . International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 82 . WHO Drug Information . 33 . 3 . 10665/330879 . free . World Health Organization .